stocks logo

ATYR Earnings

aTyr Pharma Inc
$
5.275
+0.045(0.860%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of aTyr Pharma Inc(ATYR) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of aTyr Pharma Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
-2025-08-07After Hours-0.18-0.22-22.2212.00M0.00-100.00+1.15-
-2025-03-13After Hours-0.23-0.18+21.74210.00K0.00-100.00-0.50-5.76
-2024-11-07--0.22-0.23-4.5518.57K---4.62+8.31
-2023-11-09--0.21-0.20+4.761.20M353.00K-70.58-5.74-8.20
-2023-08-09--0.27-0.22+18.52611.67K----
-2023-05-09--0.39-0.29+25.64----0.47+20.09
-2023-03-09--0.48-0.26+45.83----9.18-7.29
-2022-11-10--0.45-0.46-2.22---+4.85+4.85
-2022-08-15--0.43-0.44-2.33---+2.82+3.67
-2022-05-09--0.34-0.44-29.41----8.07-21.64

ATYR Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, aTyr Pharma Inc reported performance for , announced on 2025-08-07. The company achieved an EPS of -0.22, compared to analyst estimates of -0.18 by -22.22% . Revenue for the quarter reached 0.00 compared to expectations of 12.00M by -100.00% .
The stock price reacted with a 1.15% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in aTyr Pharma Inc growth trajectory and strategic initiatives.

ATYR Earnings Forecast

Looking ahead, aTyr Pharma Inc(ATYR) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 227.27%, while EPS estimates have been Revise Downward by -8.17%. For the upcoming Q1 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 59.37% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in aTyr Pharma Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between ATYR's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
up Image
+227.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.17%
In Past 3 Month
EPS Estimates for Q1 2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+59.37%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:6.55M
--
EPS Estimate-Annual FY 2025:-0.61
Stock Price5.28

ATYR Revenue and EPS Performance: A Historical Perspective

aTyr Pharma Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-08-07,After Hours):
EPS: -0.22 (Actual) vs.-0.18 (Estimate) (-22.22%)
Revenue: 0.00 (Actual) vs. 12.00M (Estimate) (-100.00%)
Price Reaction: 1.15%(1-Day), %(5-Day)
(2025-03-13,After Hours):
EPS: -0.18 (Actual) vs.-0.23 (Estimate) (21.74%)
Revenue: 0.00 (Actual) vs. 210.00K (Estimate) (-100.00%)
Price Reaction: -0.50%(1-Day), -5.76%(5-Day)
(2024-11-07,):
EPS: -0.23 (Actual) vs.-0.22 (Estimate) (-4.55%)
Revenue: 0.00 (Actual) vs. 18.57K (Estimate) (%)
Price Reaction: -4.62%(1-Day), 8.31%(5-Day)
Earnings Reaction
The chart below shows how ATYR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ATYR sees a +4.52% change in stock price 10 days leading up to the earnings, and a -4.01% change 10 days following the report. On the earnings day itself, the stock moves by -0.99%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed 1.15% on the day following the earnings release and then changed by 0.67% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Summary
Neutral
2025-03-15
The earnings call reveals a mixed sentiment. Positive factors include the significant milestone payments from the Kyorin agreement and a healthy cash position. However, the ATM offering may dilute share value, and the Q&A section highlights some uncertainties, such as lack of clarity on patient data and FDA interactions. The increase in R&D expenses suggests ongoing investment but may impact short-term profitability. Overall, these mixed signals suggest a neutral market reaction, with no clear catalyst for a significant stock price movement.
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Summary
Neutral
2025-03-13
The earnings call summary presents mixed signals: a strong cash position and potential milestone payments are positives, but increased R&D expenses and unclear responses in the Q&A raise concerns. The ATM offering could negatively impact stock price. Overall, the sentiment is neutral as positive cash flow and potential partnerships are balanced by financial and operational uncertainties.
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Summary
Neutral
2025-03-13
The earnings call reveals a mixed sentiment: strong cash position and commercial readiness are positive, but increased expenses and limited revenue growth are concerns. The Q&A highlights uncertainty, with management avoiding specifics on trial participation and FDA guidance. No new partnerships or guidance changes were announced. The market reaction is likely neutral, with balanced positive and negative factors.
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Summary
Neutral
2025-03-13
The earnings call summary shows mixed signals: strong cash position and potential milestone payments are positive, but the ATM offering and high R&D expenses are negative. The Q&A reveals regulatory challenges and management's reluctance to provide specifics, adding uncertainty. Despite cash sufficiency, these factors balance out to a neutral sentiment.

FAQ

arrow icon

What were the key highlights of ATYR’s latest earnings report for ?

ATYR reported its earnings on 2025-08-07, showcasing a revenue of 0.00 against an estimate of 12.00M, resulting in a -100% surprise. The EPS was -0.22, surpassing the expected -0.18 by -22.22% . The stock experienced a 1.15% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
arrow icon

How did ATYR’s stock price react after the earnings release?

arrow icon

What are the revenue and EPS estimates for ATYR for undefined?

arrow icon

How does ATYR’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from ATYR’s next earnings report?

arrow icon

What is the sentiment in aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Summary?